文献速递肾小球疾病

标准化化学发光免疫法检测原发性膜性肾病抗PLA2R抗体的性能评估

Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2019-11-22

本研究评估新型标准化化学发光免疫法(ChLIA)检测抗PLA2R抗体的诊断性能,并与ELISA和RC-IFA比较。155例活检证实的原发性膜性肾病患者和154例疾病对照的血清分析显示,ChLIA临床敏感性83.9%,高于ELISA的73.5%,与RC-IFA的83.2%相当,特异性均≥99.4%。ChLIA与RC-IFA定性一致率99.4%,与ELISA一致率94.5%。

要点

  • ChLIA检测抗PLA2R抗体敏感性83.9%,高于ELISA的73.5%,与RC-IFA的83.2%相当。
  • ChLIA特异性≥99.4%,与ELISA和RC-IFA相似。
  • ChLIA与RC-IFA定性一致率99.4%,与ELISA一致率94.5%。

核心结论

  • 新型抗PLA2R ChLIA在检测原发性膜性肾病患者方面优于ELISA,与RC-IFA几乎完全一致,可作为准确检测抗PLA2R抗体的有前景的替代工具。

研究设计与样本

  • 研究纳入155例活检证实的原发性膜性肾病患者和154例疾病对照,采用新型ChLIA、ELISA和RC-IFA检测血清抗PLA2R抗体。

主要发现

  • ChLIA临床敏感性83.9%,ELISA为73.5%,RC-IFA为83.2%。
  • ChLIA、ELISA和RC-IFA特异性均≥99.4%。
  • 在ELISA阴性的pMN样本中,ChLIA和RC-IFA分别有39.0%和36.6%为阳性。
  • ChLIA与ELISA定性一致率94.5%,与RC-IFA定性一致率99.4%。

临床怎么用

  • ChLIA可用于原发性膜性肾病患者抗PLA2R抗体的准确检测,具有快速周转和全自动随机存取处理的优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Autoantibodies against the M-type phospholipase A2 receptor (PLA2R) are important markers in the diagnosis and monitoring of primary membranous nephropathy (pMN). For the detection of anti-PLA2R autoantibodies, a standardized recombinant cell-based indirect immunofluorescence assay (RC-IFA) and enzyme-linked immunosorbent assay (ELISA) are widely used, the former providing higher sensitivity but lacking a finely graduated quantification of antibody titers. In this study, we evaluated the diagnostic performance characteristics of a novel standardized chemiluminescence immunoassay (ChLIA) by comparison with the established anti-PLA2R test systems. METHODS: Sera from 155 patients with biopsy-proven pMN and 154 disease controls were analyzed for autoantibodies against PLA2R by the novel ChLIA as well as by ELISA and RC-IFA. RESULTS: The clinical sensitivity of the ChLIA (83.9%) was higher compared with ELISA (73.5%) and equaled that of RC-IFA (83.2%), at similar specificities (≥99.4%). Among ELISA-negative pMN samples, ChLIA and RC-IFA yielded positive results in 39.0% and 36.6%, respectively. The qualitative agreement amounted to 94.5% (ChLIA vs. ELISA) and 99.4% (ChLIA vs. RC-IFA). CONCLUSION: The novel anti-PLA2R ChLIA outperforms the ELISA in detecting patients with pMN and demonstrates almost perfect agreement with RC-IFA. It thus presents a promising alternative tool for accurate anti-PLA2R testing, with the advantage of rapid turnaround times and fully automated random-access processing.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Dähnrich C, Saschenbrecker S, Gunnarsson I, et al. Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy. Kidney Int Rep. 2019. PMID: 32043032. doi:10.1016/j.ekir.2019.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。